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IN mice passive immunity to leukaemic homografts has been obtained by
transfer of sera containing iso-antibodies against both the H-2 antigens and the
so-called X-type antigens, examples of which have been found in several leukoses
(Amos and Day, 1957 ; Gorer and Amos, 1956 ; Gorer, personal communication).
Histologically, leukaemic grafts can be seen to be destroyed by a massive exuda-
tion offluid into thegraft on the fourth and fifthday ; thereafter host cells appear
which act only as scavengers (Gorer, 1958). Sarcomatous grafts, on the other
hand, are invadedby a syncytium ofhost cells whichengulfanddestroy thegraft.
The antigens of the H-2 system are the major antigenic factors controlling the
fate ofhomografts in mice, and are determined by a long series of alleles on the
ninth chromosome. Present knowledge of this system has been reviewed by
Gorer and Mikulska (1959).
These results suggested that iso-antibodies play an important part in homo-
graft rejection, particularly of leukotic grafts, and might have a detectable effect
in vitro. There have been fewpurely in vitro studies of this effect. Miller (1956)
failed to show any effect upon cells growing in tissue culture of exposure to iso-
antibody ; the cells were ofepithelialorigin and the presence ofactive complement
was not ensured. Mouse serum is usually devoid of complementary activity
in vitro, and Ritz (I911) stated that mouse serum was deficient in the
" end-piece
"
of complement, whilst Brown (I943) believed it to lack the second component,
C'2. McGhee (1952) demonstrated murine complement in vitro and convincing
evidence ofitsactivity in vivo has beenprovidedby theexperiments with diffusion
chambers repo'rted by Algire, Weaver and Prehn (1957), who obtained lysis of
Hela cells and by Amos and Wakefield (1958) who demonstrated lysis of mouse
leukotic cells.
Schrek (1936) has described a method of distinguishing viable and non-
viable cells in asuspensionby means ofdifferentialstaining, using eosin, methylene
blue and trypan blue, dyes which stain non-viable cells, whilst viable cells are
not affected, asPappenheimer (1917) had shown many years before. Atechnique
for studying the effect of murine iso-antisera in vitro was briefly reported by
Gorer and the present author (Gorer and O'Gorman, 1956) which used Schrek's
method. The technique did not prove completely reliable in further use and a
more satisfactory modification is now presented, together with a detailed study ofthe nature ofthe antibody, ofthe antigenic system involved and ofthe effect of
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cytotoxic iso-antibody upon normalleucocytes and upon several leukoses and two
sarcomata.
MATERIALS
Mice.-The mice used were from the inbred lines Strain A, BALB/c, C3H and
C57BI, maintained in the laboratory of Dr. P. A. Gorer, and also the progeny of
the backcross (A x C57BI) F, X C57BI.
Complement.-Guinea-pig complement was used, obtained by cardiac puncture
and stored at -20' C. until needed.
Tumours.-Two ascites leukoses were used, EL4 (C57BI strain) and CL2
(BALB/c). EL4 has been maintained by transplantation for many years, and
will not grow subcutaneously in foreign strains, but sometimes will do so intra-
peritoneally. CL2 is of recent origin and is strain specific. Two other leukoses
CLI (BALB/c) and EL8 (C57BI) are of recent origin and are strain specific, but
produce generalized leukoses with massive enlargement of the spleen. Three
ascites sarcomata weie used, BP8 (C3H strain) and Sal and MTC IA (both A
strain). All of these tumours sometimes grow progressively if inoculated intra-
peritoneally in large doses into foreign strains. In moderate dosage, sub-
cutaneously, they are strain specific. Three other strain specific tumours were
used-the mammary carcinomata EMT (C57BI), AMT (A strain) and CTI
(BALB/c) and the leukosis EL5; all were maintained as solid subcutaneous
growths.
-1,3o-anti8era.-Details of the hyper-immune iso-antisera used will be given at
the appropriate places in the text.
Dye8.-Both eosin and trypan blue were used at a concentration of 1/2000 in
Tyrode's solution, filtered after preparation. No significant difference was obser-
ved in the results of parallel experiments using the two dyes, but trypan blue
gives more clear-cut staining.
METHODS
Prepai-ation of cell su8pen8ions
1. From a8cite-s tumours.-The ascites was diluted in Ringer's solution in
the case of the non-haemorrhagic leukotic ascites, and in 3 per cent sodium
citrate in the case of the haemorrhagic sarcomatous ascites. Total cell counts
were made at once, and the dilution adjusted with normal mouse serum and
Ringer's solution to give a final count of approximately 30,000/irriM.3 in I : 5
normal mouse serum. Viability counts gave from 0-5 per cent stained cells in
the case of the ascites leukoses, and about 0-10 per cent in the ascites sarcomata.
2 From 8pleen.-The same method was used for both normal and leukotic
spleens. The animal was killed with chloroform, the abdomen opened, the spleeii exposed and the splenic artery and vein were cut with fine scissors. A 10 ml.
syringe was fitted with a fine intra-dermal (No. 26 G.) needle and filled with
sterile Ringer's solution. The point of the needle was introduced under the
capsule of the spleen and light pressure applied to the plunger. Immediately a
small white areaappeared around the needlepoint, which extended as the pressure
was maintained. After about I ml. had been injected the needle was withdrawn
and reinserted in a different position. In this way the whole spleen was gradually perfused. If the splenic vessels are not divided, the liver and kidneys can be,337 CYTOTOXIC ACTIVITY OF MLTRINE ISO-ANTISERA
perfus,ed at the sametime, and this isprobably a more convenient way ofpeffusing
these organs than by cannulation of the appropriate artery or by intra-cardiac
injection. After perfusion the spleen was excised, freed from fat and finely
minced with small scissors and suspended in I : 5 normal mouse serum. Small
clumps were broken up bygentlepipetting, and the larger clumps which remained
were allowed to settle out. The concentration was adjusted to a final figure of
approximately 30,000 leucocytes/MM.3 Viability counts usually showed about
5-10 per cent stained cells.
Titration ofcompleinent
Undiluted guinea-pig serum was often toxic to the target cells whilst its
complementary activity declined rapidly on dilution. It was therefore titrated
in terms of its ability to complement the cytotoxic activity of iso-antisera. A
serum known to be toxic for the target cells was used at a dilution of I : 5 and the
complement was titrated in the dilution range I : I to I : 4 ; it was seldom active
at greater dilutions. Controls of normal serum and another iso-antiserum known
not to be toxic for the target cells were used.
Antibody titration
The cytotoxic activity of an antiserum was usually investigated in the form
of a titration, to exclude zoning.
Doubling dilutions of each antiserum to be tested were made in I : 5 normal
mouse serum. Control tubes, containing only the diluted normal serum, were
included. A volume (0-05 ml.) of cell suspension was added to each tube and
finally a volume of diluted complement. The rack was incubated at 37' C. for
45-75 minutes, except in the experiments on the timing of the reaction. After
incubation dye was immediately added to all the tubes to make a final dilution of
I : 10. The tubes were left for a few minutes before counting to ensure correct
staining.
Two methods ofreading the titration were employed. In the first, differential
counts were made on each tube. In the second, the two control tubes were counted
and the cells from the rest of the row were streaked across a glass slide and
inspected. The results were expressed as +++, ++ etc., the term AC being used when the effect was almost complete and there were virtually no viable cells
to be seen; a negative was scored when the number of stained cells approached that in the control tubes. This method is entirely satisfactory for the routine
titration of a serum, but the method expressing the result as a percentage viable
count was found to be more delicate when comparative work was being done.
Results obtained by the two methods are strictly comparable.
Haemagglutination
The "human serum: dextran
" technique of haemagglutination described
by Grorer and Milulska (I954) was used for genetic studies and titration of sera.
In vivo ab8orption
Amos (1955) has described the in vivoabsorption ofantibodyby micepossessing the appropriate antigen. lf a potent serum such as BALB/c anti-C57BI, isPATRICK 01GORMAN 338
injected intra-peritoneally into C57BI mice, the haemagglutinin titre in the
recipients' serum fallsrapidly and will not be detectable after twohours, even if as
much as 0-5 ml. of antiserum is injected. The absorption in all cases is specific
and non-specific absorption does not occur.
RESULTS
The morphology of the damaged cells
There was considerable variation in the appearance of the stained cells.
Whilst some retained a normal rounded outline, in which the nucleus could
barely be seen, other cells became swollen, sometimes grossly so. The outline of
these cells became irregular and indistinct and occasionally the cell membrane
appeared to have developed bubbles. In the more severely affected cells the
nucleus could be clearly seen when trypan blue was used as the stain. Actual
lysis of the cells was not seen.
Effect on normal and malignant cells
No significant difference could be detected between the results obtained using
normal or leukotic white cells, but ascites leukoses were preferable as the suspen-
sions contained less debris and fewer stained cells than those made from spleen or
sarcomatous ascites.
The effect of heat
Heating the antiserum at 56' C. for 30 minutes was without effect on the titre.
Rate qf reaction
Murine iso-antisera appear to be toxic to homologous cells even after very
short exposure, in the presence of active complement. In an experiment in
which BALB/c anti-BP8 was tested on normal C3H leucocytes, 90 per cent of the
target cells were stained after only 10 minutes' incubation at 37' C. The control
at this stage contained only 5 per cent non-viable cells. After 20 minutes'
incubation 95 per cent of the cells were dead ; the increase is probably not
significant. On the other hand, prolonged incubation, i.e. for more than'21
hours produced high numbers of dead cells in the control tubes.
Time of appearance ofcytotoxic antibody
Groups offour mice were bled on successivedays after inoculation with tumour
suspension. The blood from the individuals of each group was pooled and the
cytotoxic activity of the serum tested on appropriate cells. Thehaemagglutinat-
ing titre was determined at the same time.
The results of one such experiment are expressed graphically in Fig. 1. The
animals were BALB/c, inoculated subcutaneously with EL4. The sera were
tested for cytotoxicity on EL4, and for haemagglutinating activity on A and
C57BI red cells. As can be seen from the graphs neither cytotoxin nor haemag-
glutinin was present on the eighth day after inoculation. Both appeared on the
ninth day, and the titres rose together on the same day.339 CYTOTOXIC ACTIVITY OF MURINE ISO-ANTISERA
The Nature of the Antigenic System
Absorption, in vivo, ofanti-X
Intheinitialstagesofthisinvestigation it wasthought that theantigen involved
was the so-calledantigen X describedby GorerandAmos (1956), to which reference
has already been made. This hypothesis was tested by absorption experiments,
using the method of in vivo absorption described by Amos (1955). One such
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FIG. I.-Time of appearance ofiso-antibody.
experiment is illustrated in Table 1. An injection of I-0 ml. of a sample of
BA-LB/c anti-EL4 was given intra-peritoneally to each of three BALB/c mice
and three (C57BI x A) F, mice. These animals were bled out 24 hours later
and the sera from each group were pooled and tested on EL4, in parallel with
normal mouse serum. BALB/c anti-EL4 serum contains the H-2 antibodies
anti-E and anti-Db , and these should not be absorbed by passage inBA-LB/c. They
should be absorbed, however, by passage in C57BI, or C57BI Fl, and this in fact
did occur. When tested by haemagglutination the F, passaged serum gave a340 PATRICK 05GORMAN
TABLEI.-Absorption in vivo ofCytotoxic Antibody
BALB/c Percentage non-viable cells at Haemagglutinin
anti-EL4 antiserum dilutions of titres
passaged r A-
in 1/1 1/2 1/4 1/8 A strain C57BI
BA-LB/c 71 93 100 100 1- -.4096 1: 64
(C57BI x A)F, 1 4 8 5 1:256 0
titre of only I : 256 for strain A cells (which would detect anti-E) and no titre
for C3H cells (also anti-E) nor for C57BI cells (anti_Db and anti-E) whilst the
BALB/c passaged serum gave titres of I : 4096 for A cells, I : 512 for C3H
and I : 64 for C57BI. As can be seen from the table, the serum passaged in the
(C57BI x A) F, showed no residual cytotoxic activity for E14 tumour cells killing
a maximum of only 8 per cent. The serum passaged in BALB/c on the other
hand killed 100 per cent of the target cells. The cytotoxic antibody had been
absorbed out in a similar manner to the haemagglutinating antibody.
Sera of this type (BALB/c anti-EL4) when tested in vivo, can be shown to
contain anti-X. This antibody is not absorbed when the serum is passaged in
C57BI or C57BI Fl, and should therefore have been detected in this experiment, if
it was in fact theantibody concerned. Even a short absorption left no detectable
cytotoxicity. 0-2 ml. of BALB/c anti-EL4 was injected into BALB/c and
(C57BI x A) Fl, and the animals were bled out after only two hours. The
cytotoxic and haemagglutinating antibodies were both absorbed by the (C57BI
x A) Fl, there being no residual activity, altho'ugh the BALB/c passaged serum
killed 80 per cent of the target cells and gave a haemagglutinin titre of I : 256
for A cells. The difference between the titre ofthe absorbed 8erum in this experi-
ment and that shown in Table I is due to the different amounts of serum give
(O-2 ml. and I-0 ml. respectively).
These results suggested that both cytotoxic and haemagglutinating antibody
were determined by the same antigenic system, in other words the H-2 system,
and a series ofexperiments was undertaken to prove this theory.
Backcross experiments
A cross was made between A x C57BI and the Fl was backcrossed to C57BI.
In these crosses some of the H-2 genes are segregating, and 50 per cent of the
progeny of the backcross will have the A strain genotype. The A strain has
the H-2 constitution CDEFHKRWYZ whilst the C57BI can be written as
DbEFKbRVZ (Gorer and Mikulska, 1959). Restricting the discussion to the
pertinent genes, the (A x C57BI) F is CDK/DbKb and the B backcross are either
DbKb/DbKb orCDK/DbKb Tissues of the animals carrying CDK will naturally
absorb the appropriate antibodies from sera.
The progeny of the B backcross were tested for the presence of these antigens
by haemagglutination and divided into H-2 positive (i.e. carrying CDK) and H-2
negative (lacking CDK). Equal numbers of H-2 positive and negative animals
were tested by the technique of in vivo absorption (Amos, 1955). All were given
an intra-peritoneal injection of 0-1 or 0-2 ml of C57BI anti-MTC serum; MTC was
an A strain sarcoma and this serum contained anti-C, anti-D and anti-K.
The mice were bled after 18 hours and the sera tested for cytotoxicity. An
excellent fit was obtained with the results of typing by haemagglutination. Of441 CYTOTOXIC ACTIVITY OF MURINE ISO-ANTISERA
12 B backcross mice 6 were H-2 positive and 6 were H-2 negative ; none of
the sera of the H-2 positive group showed any residual cytotoxic activity. whilst
those of all the H-2 negative mice showed marked cytotoxicity after absorption.
No discrepancies were found.
The cytotoxic antibodies, anti-D and anti-Kb
Anti-Dk.-Sera of the type A anti-C3H (H-2a anti-H-2k) can be shown to
contain haemagglutinins only erratically but are toxic for C3H leucocytes and
sometimes for the C3H sarcoma BP8. A sample of H-2a anti-H-2k was kindly
prepared by Dr. George Snell in the I-R strains AKK and AKR established by
him. These strains differ only at their H-2 sites, and so any antibody formed
must beagainst an H-2 component. This serum was also toxic forC3Hleucocytes,
killing 74 per cent, as against 4 per cent in the control. A sample of H-2a anti-
H-2k prepared in this.laboratory killed 90 per cent ofthe leukotic cells. Neither
serum was toxic for BALB/c or C57BI leucocytes. Gorer and Mikulska (1959)
quote evidence from their crossover combinations to show that this new antigen
k should be on the D part of the chromosome and propose the tentative label D .
Anti-Kb.-The antigenicity of the alleles of K was investigated using the
crossover combinations described by Gorer (1956). A-n antiserum was prepared
in the D-K+ (H-2h) crossover against the C57BI (H-2b) tumour EL4. It was
found to be toxic for cells from'C57BI and the D+K- (H-2i) crossover, but was
not toxic for the B+E- (H-2g) crossover. The D+K- crossover could only have acquired its antigen in the K position from H-2b, whilst the B+E- cross-
over could have acquired this antigen from either H-2b or H-2d. If it had come
from H-2b then this serum should have been toxic for the B+E- cells. That
the reverse happened shows that there must be two different antigens in the K
position on H-2b and H-2d,' and the newly identified antigen on H-2b has been
termed K b The effect could not be due to an antigen in the C position, for it
could only have come from H-2b and the serum would therefore have been toxic
for B+E- cells.
The Susceptibility ofLeukose,3 and Sarcomata to Cytotoxic Antibody
A. The leukoses
EL4.-Very many experiments were performed in which EL4 cells were used
as the target. This leukosis is highly susceptible to antibody, and typically 90-100 per cent of the EL4 cells are killed against 1-5 per cent in the control
tubes.
EL8.-Suspensions of leukotic cells made from a spleen invaded by this
leukosis contain few stained cells. It isfullysusceptible to the action ofantibody. When tested with BALB/c anti-EL4 non-viable cell counts of between 84 and
96 per cent were obtained depending on antibody dilution, wliilst the control
tubes showed 16-19 per cent stained cells.
CLI and CL2.-CLI produces massive splenic enlargement, and CL2 is an
ascites leukosis. In an experiment in which CLI and EL4 were tested in parallel with BALB/c anti-EL4 and A anti-CTI, the following results were obtained.
The BALB/c anti-EL4 killed 100 per cent EL4 cells but only 18 per cent CLI ;
on the other hand, the anti-CTI killed only 2 per cent EL4 and 69 per cent CLI.
Both sera were used at a dilution of I : 1. In another experiment the BALB/cPATRICK 05GORMAN 342
leukoses were tested with three different sera, namely A anti-ELI, C57BI anti-
BALB/c and A anti-CTI. A anti-EL4 showed some slight toxic activity aorainst
CLI, for at a dilution of I : 2 it killed 20 per cent of the cells, compared with 10
per cent in the control tubes; differences of this order may not be significant.
The two anti-BALB/c seraproduced 75 and 73 per cent stained cens respectively.
In the case of CL2 there was no difference in the non-viable cell counts in the A
anti-EL4 and control tubes. This leukosis ifanything was slightly more suscep-
tible to the cytotoxic effect of the anti-BALB/c sera, the figures being 81 and 86
per cent in the two cases.
B. The sarcomata
Details of the two sarcomata BP8 (QH) and Sal (A strain) have been given
above. There was a striking difference between the results obtained with the
two tumours.
BP8.-Most of the experiments on BP8 used samples of BALB/c anti-BP8,
but A anti-BP8 was also included; sera of the latter type contain anti-D k and
have been discussed above. The BP8 tumour cells are not as susceptible as
leukotic or normalleucocytes to the action ofantibody ; in mostexperiments non-
viable cell counts were of the order of 40 to 60 per cent at the lower dilutions of
antibody and on only one occasion did the count exceed 70 per cent. The
difference between thesusceptibilities ofBP8 and normal C3H leucocytes is shown
in Table II, which illustrates an experiment in which both were tested with A
TABLEII.-Cytotoxic Effect on BP8 and Normal Leukcocytes
Percentage non-viable cells at antiserum* dilutions of:
r
Target cells Controls 1 :2 1 : 4 1 :8 1 :16 1 :32 1 :64
BP8 23 21 55 63 51 52 30 16
CH3 leucocytes 14 11 96 92 95 93 81 44
* Antiserum was A anti-BP8-see text.
anti-BP8. When tested withBALB/c anti-BP8 inparallel withEL4, BP8 showed
less than 45 per cent stained cells, whereas the leukosis showed 95 per cent.
Sal.-Sarcoma 1 appears to be completely insensitive to the in vitro cytotoxic
activity of iso-antisera, and despite repeated testing, with different sera, no
convincing evidence was obtained of any toxic effect. A strain leucocytes are
as fully sensitive to antibody as are the leucocytes of any other strain. Table
III shows the results oftests made inparallel on Sal and A strainleucocyteswith,
TABLIF, III.-Cytotoxic Effect on Sarcoma I
Percentage non-viable cells at antiserum
dilutions of
r
A-nti-serum Controls I : 2 1: 4 1 : 8 1 :16 Target cells
C3H 1 2 5 3 7 2 Sal
anti-AiMT 8 6 90 85 56 9 A strain
leucocytes C57BI 7 9 3 8 Sal
anti-MTC 95 89 91 90 A strain
leucocytes
BALB/C 1 6 10 11 Sal
anti-BP8 91 95 96 91 A strain
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three different sera, all of which contained antibodies toxic for A strain white
cells. AMT and MTC are both A strain tumours-, whilst BALB/c anti-BP8
contains anti-E and anti-K both of which are toxic for A strain leucocytes.
Results of an experiment in which one anti-serum was tested on cells of one
leukosis and the two sarcomata are given in Table IV, and provide striking
TABLF, IV.-Cytotoxic Effect upon Three Tumours
Percentage non-viable ceRs at antiserum*
dilutions of
r
Target ceRs Controls 1:2 1:4 1:8 1:16
EL4 16 12 95 98 95 91
BP8 1 6 61 49 56 61
Sal 3 2 5 7 3 9
Antiserum was BALB/c anti-BP8.
evidence of the difference in susceptibility to antibody of the cells of the three
tumours.
DISCUSSION
Thefunction ofcirculatingantibody inhomograftrejection has beenthesubject of much discussion. By technical modifications of Gorer and Mikulska's (1954) method H-2 antibodies have now been detected in mice before the histological
onset of the homograft reaction (Gorer, Mikulska and O'Gorman, 1959) and the
demonstration in the present work that these antibodies have a cytotoxic effect
on leukoses and sarcomata is evidence against a purely cellular mechanism. The
cytotoxic technique is not as sensitive in antibody detection as is the human
serum: dextran method, but has been the means of identifying two "new"
b k H-2 antigens, K and D
No evidence was found of any in vitro cytotoxic effect of the anti-X described
by Gorer and Amos (1956). This may be because anti-X is not toxic under these
experimental conditions, or because anti-X is not a cytotoxic but a cytostatic antibody, holding the graft in check until the body's defences complete the
rejection.
Circulating antibody plays a much more decisive role in the destruction of
leukotic arafts than in any others, and for this reason it would seem that leukotic
cells or normal white cells would be the material of choice for the investigation ofthe action ofantibody. It is unfortunate thatAlgire and his co-workers did not
include such cells among thetargets whichtheyplaced in their diffusion chambers.
Cells such as those ofmammary carcinomata may becompletely insensitive to the
action of antibody, and in any case it is essential to ensure an adequate level of
antibody within the chamber, antibody which has not been produced there by host cells. Amos and Wakefield (1958) having ensured an adequate antibody level have been able to demonstrate lysis of leukotic cells within chambers from
which host cells had been excluded.
Lysis of target cells has not been observed in the present work, and usually the cell morphology is little affected. This absence ofcytolysis in vitro, of course,
may not be an accurate reflection ofin vivo conditions, but ifit is accurate then it
conforms very weR with thehistological appearances ofregressinggrafts. Histio-
cytic invasion and phagocytosis follow the exudation of fluid into leukotic grafts,
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and it is only in such grafts that cytolysis is observed before this invasion. In
grafts of sarcomata little or no cytolysis occurs before the invasion of the graft
by the syncytium of host histiocytes. The function of the circulating antibody
may not be the destruction of thegraft, but rather the killing of the graft cells to
prepare them for the phagocytes which have yet to come, and the differences in
the homograft reactions elicited by different tumours (or tissues) may be a reflec-
tion of their differing susceptibility to the toxic action ofantibody.
Certainly, most marked differences were found in the antibody susceptibilities
of the various tumours which were used in the present work. The sarcomata; do
not Qhow the uniform susceptibility of the leukoses, and Sal appears to be com-
pletely insensitive to the toxic action ofantibody in vitro, although it does have
an effect in vivo. BP8 is susceptible to the toxic action of antibody in vivo as
has been shown by the neutralization technique (Gorer, 1956) and by passive
immunity studies, but only partly so in vitro.
Snell (1957) has propounded a classification of transplantable tumours into
three types, based on their susceptibility to the action of antibody. The first
class comprises tumours which are highly susceptible and includes Gorer's A
strain leukaemia, the BAGG rat lymphosarcoma, the Brown-Pearce carcinoma
(Kidd's subline) EL4 and other tumours, all oflymphoid origin. Not only EL4
but also the other leukoses used in the present work have been shown by Gorer to
be susceptible to the action of antibody by passive immunity studies, and they
are all susceptible to the cytotoxic effect in vitro. Snell's second category com-
prises tumours with low but demonstrable susceptibility to humoral antibodies,
and includes Sal and the lymphosarcoma 6C3HED. These tumours respond to
the action of antibody by enhanced rather than inhibited growth when passive
transfer of antiserum is used; 6C3HED has been found to be slightly and irregu-
larly susceptible to the toxic effect of antibody by the neutralization technique
(Mitchison, 1955). The in vitro results confirm Snell's (1957) separation of EL4
and Sal into different categories, but it is difficult to allocate BP8 to one or the
other, for pre-treatment of the host with antiserum produces passive immunity
orenhancement ofthe tumourdepending on the dose used(Gorer andKaliss, 1959),
and about 50 per cent of the cells are killed in vitro. The third category includes
tumours which are completely insensitive to the action of antibody, and Snell
(1957) puts into this class the adenocarcinoma D1905, fibrosarcoma S620 and
perbaps the adenocarcinoma C3HBA, which was tested by Algire, Weaver and
Piehn (1954) in a diffusion chamber, and the tumour B3 with which Miller (1956)
failed to show a cytotoxic effect ofiso-antibody in tissue culture.
Kaliss (1958) believes that immuiiological enhancement is due to a direct
stimulant effect ofantibody upon the tumour cells, so that the tumour is altered
in some way and is thus better able to withstand and overcome the hosts' reaction.
The present author (O'Gorman and Mikulska, 1960) by absorption experiments
has demonstrated marked deficiencies of the H-2 antigens E and K from the cells
of Sal, a tumour which is very readily enhanced. Sal may be insensitive to
cytotoxic antibody because ofits antigenic deficiencies, but this need not preclude
a stimulant effect ofthe antibody on the cell. Similar antigenic loss has not been
studied with other tumours, but it is known to occur in the early transplant
generations oftransplantable tumours.
Gorer and his co-workers have shown that circulating antibody when passively
transferred will protect the host against a graft of at least some tumours, and theCYTOTOXIC ACTIVITY OF MURINE ISO-ANTISERA 345
neutralization technique has been widely used to demonstrate the toxic effect of
antibody upon cells which were subsequently grafted. The work which has been
reported above has demonstrated that these antibodies are toxic in vitro. In all
cases the antigenic system involved has been the H-2 system, except for Gorer
and Amos' antigen X. It would now seem to be beyond doubt that circulating
antibody plays a very significant role in the rejection of at least certain classes of
homograft, notably the leukoses and some sarcomata, and although its role in
the rejection of grafts of some normal tissues, for example skin, is admittedly a
minor one, it can no longer be held that the mechanism of homograft rejection
is entirely cellular, or that this major antibody has no function. The cellular
factors responsible for homograft rejection may in fact be cell-bound antibodies.
SUMMARY
A method has been described for demonstrating the cytotoxic action ofmurine
iso-antisera in vitro. These cytotoxic antibodies are directed against the H-2
system of antigens and two previously unknown alleles Dk and Kb have been
identified. The effect of iso-antibody on normal leucocytes and several tumours
has been described, and the significance of these results and their bearing on the
role of circulating antibody in the homograft reaction discussed.
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